Evidence map›Paper›PMID 39794361›Full record

ArticleNature communications2025

Coherent Anti-Stokes Hyper-Raman Spectroscopy.

Kazuki Inoue, Masanari Okuno

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Measurement of a Preresonant Hyper-Raman Hyperpolarizability.The journal of physical chemistry letters · 2026
    Article
  4. Article
  5. Mixed Domain IR-Hyper-Raman Four Wave Mixing Spectroscopy.The journal of physical chemistry letters · 2026
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kazuki InoueDepartment of Basic Science, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo, 153-8902, Japan.ORCID http://orcid.org/0009-0001-8245-2443
Masanari OkunoDepartment of Basic Science, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo, 153-8902, Japan. cmokuno@g.ecc.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-3682-9350

Funding

MEXT | Japan Science and Technology Agency (JST) JPMJFR211KMEXT | Japan Society for the Promotion of Science (JSPS) 21K04975MEXT | Japan Society for the Promotion of Science (JSPS) 21KK0091MEXT | Japan Society for the Promotion of Science (JSPS) 23KJ0790
6 · The paper itself

Abstract

Coherent Raman scattering spectroscopies have been established as a powerful tool for investigating molecular systems with high chemical specificity. The existing coherent Raman scattering techniques detect only Raman active modes, which are a part of the whole molecular vibrations. Here, we report the first observation of coherent anti-Stokes hyper-Raman scattering (CAHRS) spectroscopy, which allows measuring hyper-Raman active vibrations at high speed. The CAHRS process relies on a fifth-order nonlinear process that combines hyper-Raman scattering with coherent Raman scattering. Observed signals are proven to come from the CAHRS process through various experiments concerning the dependences of the signals on incident laser powers, time-delay, polarizations, and selection rules of molecular vibrations. Comparisons of CAHRS signals with spontaneous hyper-Raman signals from para-nitroaniline solutions and benzene liquid manifest much higher signal-to-noise ratios of CAHRS signals than spontaneous hyper-Raman signals. This study illustrates that CAHRS spectroscopy can offer additional information on molecular vibrations unobtainable from the present coherent Raman techniques at a much higher speed than spontaneous hyper-Raman spectroscopy.

Identifiers

PMID39794361
PMCPMC11723959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.